Novo Nordisk | NVO - Cash And Equivalent


Novo Nordisk reported DKK21.13B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
ANI Pharmaceuticals USD 360.21M 49.04M Jun/2026
Aurora Cannabis CAD 64.69M 8.33M Mar/2026
Bausch Health Companies USD 1.83B 526M Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Canopy Growth CAD 364.68M 6.64M Mar/2026
Corcept Therapeutics USD 111.04M 2.3M Jun/2026
Drreddys Laboratories INR 15.37B 3.29B Mar/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Merck USD 6.85B 1.52B Jun/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Novartis USD 7.62B 739M Jun/2026
Novo Nordisk DKK 21.13B 17.81B Mar/2026
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Pacira USD 205.88M 61.57M Jun/2026
Perrigo USD 357.2M 174.4M Mar/2026
Phibro Animal Health USD 61.42M 6.49M Jun/2026
Prestige Brands USD 89.13M 25.26M Jun/2026
Sanofi EUR 6.35B 806M Jun/2026
Supernus Pharmaceuticals USD 179.95M 4.92M Jun/2026
Zoetis USD 1.48B 465M Jun/2026